Step Therapy Policy - Medicare Part B
Customize your policy alerts
Sign up for Baylor Scott & White Health Plan Policy 307 alerts
Get alerted when Policy 307 changes without checking for updates manually.
Monitor payer policy activity
Governs step therapy for Medicare Part B outpatient drugs and certain devices. Non-preferred products generally require a new start, failure or intolerance/contraindication to applicable preferred alternatives, and applicable CMS or Plan criteria.
The policy added bendamustine, bone antiresorptive therapy, and taxane classes.
Cimerli was removed from the preferred list because commercialization was paused.
Sickle cell gene therapy policy references and Pavblu were added, and step therapy was clarified to apply to all preferred drugs.
The policy added a non-muscle-invasive bladder cancer treatment class and denosumab biosimilars to bone antiresorptive therapy.
Denosumab biosimilars were removed for Prolia and added for Xgeva, and an anti-emetic class was added.
The methotrexate class was removed.
The infliximab class was updated to include specific drug agents, and Vykoura was added to the leucovorin class.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.